ArticlePloS one2018
Validation of Multiplex Serology detecting human herpesviruses 1-5.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Helicobacter pylori multiplex serology and risk of non-cardia and cardia gastric cancer: a case-cohort study and meta-analysis.International journal of epidemiology · 2023Pooled it
- Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Pooled it
- Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells.The Journal of experimental medicine · 2020Trial
- Family history of multiple sclerosis and long-term outcomes.Journal of neurology · 2026Article
- Burden and Correlates of Multiple Chronic Infections and Their Associations With Cancer Incidence in Chinese Adults: A Large Case-Cohort Study.International journal of cancer · 2026Article
- Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts.Blood cancer journal · 2026Article
- A scalable high-throughput serolomics platform for profiling serum antibody responses in large-scale population-based cohorts.Nature protocols · 2026Review
- Epstein-Barr virus serology in relation to the outcomes of oral and genital human papillomavirus infections in women during 3-year follow-up.Scientific reports · 2026Article
- Article
- Assessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinoma.Infectious agents and cancer · 2026Article
- Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset.Annals of neurology · 2026Article
- Human herpesvirus 7 and the risk of developing multiple sclerosis.Brain communications · 2026Article
- Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis.Clinical & translational immunology · 2026Article
- Polygenic risk score and phenome-wide association study of the Epstein-Barr virus antibody response.Frontiers in genetics · 2026Article
- Acyclic graphs to define models of relationships between human cytomegalovirus, cardiovascular disease and all-cause mortality in UK Biobank.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Epstein-Barr virus (EBV) serology and its impact on oral human papillomavirus (HPV) infection outcomes in children during early childhood.Microbiology spectrum · 2025Article
- Epstein-Barr Virus Serology Associated With Persistent Oral Human Papillomavirus Infections in Men.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025Article
- Time course and determinants of the antibody response to SARS-CoV-2 in Costa Rica: the RESPIRA study.BMC infectious diseases · 2025Observational
- EBNA-1 and VCA-p18 immunoglobulin markers link Epstein-Barr virus immune response and brain's myelin content to fatigue in a community-dwelling cohort.Brain, behavior, & immunity - health · 2024Article
- Herpesvirus Antibody Response and Occurrence of Symptoms in Acute and Post-Acute COVID-19 Disease.Viruses · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Human herpesviruses (HHV) cause a variety of clinically relevant conditions upon primary infection of typically young and immunocompetent hosts. Both primary infection and reactivation after latency can lead to more severe disease, such as encephalitis, congenital defects and cancer. Infections with HHV are also associated with cardiovascular and neurodegenerative disease. However, most of the associations are based on retrospective case-control analyses and well-powered prospective cohort studies are needed for assessing temporality and causality. To enable comprehensive investigations of HHV-related disease etiology in large prospective population-based cohort studies, we developed HHV Multiplex Serology. This methodology represents a low-cost, high-throughput technology that allows simultaneous measurement of specific antibodies against five HHV species: Herpes simplex viruses 1 and 2, Varicella zoster virus, Epstein-Barr virus, and Cytomegalovirus. The newly developed HHV species-specific ('Monoplex') assays were validated against established gold-standard reference assays. The specificity and sensitivity of the HHV species-specific Monoplex Serology assays ranged from 92.3% to 100.0% (median 97.4%) and 91.8% to 98.7% (median 96.6%), respectively. Concordance with reference assays was very high with kappa values ranging from 0.86 to 0.96 (median kappa 0.93). Multiplexing the Monoplex Serology assays resulted in no loss of performance and allows simultaneous detection of antibodies against the 5 HHV species in a high-throughput manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.